

Sarah Kelliher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4247347/publications.pdf>

Version: 2024-02-01

15
papers

165
citations

1684188

5
h-index

1474206

9
g-index

15
all docs

15
docs citations

15
times ranked

319
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1008-1014.	3.8	18
2	COVID-19 induces a hyperactive phenotype in circulating platelets. <i>PLoS Biology</i> , 2021, 19, e3001109.	5.6	108
3	Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 694-700.	0.4	2
4	Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2583-2595.	3.8	4
5	Ruling out Pulmonary Embolism in Patients with (Suspected) COVID-19: A Prospective Cohort Study. <i>TH Open</i> , 2021, 05, e387-e399.	1.4	7
6	Routine Hematological Parameters May Be Predictors of COVID-19 Severity. <i>Frontiers in Medicine</i> , 2021, 8, 682843.	2.6	13
7	Outcomes Following Acute Pulmonary Embolism in an Irish Population of over 1 Million Individuals: Opportunities for Quality Improvement and More Effective Resource Utilisation. <i>Blood</i> , 2021, 138, 2979-2979.	1.4	0
8	Comprehensive Multi-Parameter Characterisation of Circulating Extracellular Vesicles from Rivaroxaban-Treated VTE Patients Reveals Reduced Inflammation and Ameliorated Endothelial Dysfunction. <i>Blood</i> , 2021, 138, 3210-3210.	1.4	0
9	Pathophysiology of the Venous Thromboembolism Risk in Preeclampsia. <i>Hamostaseologie</i> , 2020, 40, 594-604.	1.9	6
10	The unintended consequences of a bowl of soup. <i>European Journal of Internal Medicine</i> , 2020, 74, 99-100.	2.2	0
11	Implementation of an acute DVT ambulatory care pathway in a large urban centre: current challenges and future opportunities. <i>Thrombosis Journal</i> , 2019, 17, 14.	2.1	5
12	Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation. <i>Blood</i> , 2019, 134, 2437-2437.	1.4	0
13	Higher Rates of Death and Major Bleeding Highlight the Inequities That Exist in the Care of People with Venous Thromboembolism Who Experience Social Exclusion: Findings from a Prospective Registry of 79735 Patients (RIETE). <i>Blood</i> , 2019, 134, 4677-4677.	1.4	0
14	Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease. <i>Blood</i> , 2019, 134, 4702-4702.	1.4	1
15	Estimating the Burden of Hospital-Acquired Venous Thromboembolism: The Argument for Implementation of Mandatory Risk Reduction Strategies. <i>Blood</i> , 2018, 132, 3515-3515.	1.4	1